Clinical trial · Interventional
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Evaluation of Serum Tumor Markers in Assessing the Efficacy of TP Chemotherapy Combined With Trastuzumab and Pertuzumab Dual Target Therapy in HER2-Positive Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, randomized study to compare the efficacy of TP (Taxane plus Carboplatin) chemotherapy combined with dual-HER2 blockade (trastuzumab and pertuzumab) versus TP chemotherapy plus single-HER2 blockade (trastuzumab) in patients with HER2-positive breast cancer. The study aims to evaluate treatment response and the clinical value of serum tumor markers (CEA, CA125, and CA153) in assessing therapeutic efficacy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2-positive Breast Cancer | HER2-Positive Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TP Chemotherapy + Trastuzumab | Drug | — | UNRESOLVED |
| TP Chemotherapy + Trastuzumab + Pertuzumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Experimental: Study Group (Dual-Target Therapy)
- description
- Patients received TP chemotherapy combined with trastuzumab and pertuzumab. Treatment was administered for 6 cycles, with each cycle lasting 21 days.
- interventionNames
- Drug: TP Chemotherapy + Trastuzumab + Pertuzumab
- type
- ACTIVE_COMPARATOR
- label
- Active Comparator: Control Group (Single-Target Therapy)
- description
- Patients received TP chemotherapy combined with trastuzumab only. Treatment was administered for 6 cycles, with each cycle lasting 21 days.
- interventionNames
- Drug: TP Chemotherapy + Trastuzumab
Primary outcomes (2)
- measure
- Overall Response Rate (ORR)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed HER2-positive breast cancer. * Presence of measurable lesions. * No evidence of distant metastases. * No prior surgery or chemotherapy. * Voluntarily signed the informed consent form. Exclusion Criteria: * Incomplete neoadjuvant therapy. * Incomplete clinical medical records. * Presence of distant organ metastasis. * Known allergy to study drugs. * Expected survival of less than 3 months. * Significant liver or kidney dysfunction. * Presence of hematological or immune system diseases. * Unclear pathological results. * Concurrent other malignant tumors. * Pregnant or lactating patients.
References
Publications (0)
Data not yet available